Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

abiraterone amorphous solid dispersion formulation DST-2970

An orally bioavailable, amorphous solid dispersion formulation of the steroidal compound abiraterone, with potential antiandrogen activity. Upon oral administration, abiraterone inhibits the enzymatic activity of steroid 17alpha-monooxygenase (17alpha-hydrolase/C17,20 lyase complex; CYP17A1), a member of the cytochrome p450 family that catalyzes the 17alpha-hydroxylation of steroid intermediates involved in testosterone synthesis. This may suppress testosterone production by both the testes and the adrenals to castrate-range levels.
Synonym:abiraterone KinetiSol formulation DST-2970
Code name:DST 2970
DST-2970
DST2970
Search NCI's Drug Dictionary